Table 3. Adverse Events and Serious Adverse Events^a.

Adverse Event or Reaction	No. (%) of Participants		P Valueb
	Liraglutide Treatment Group (n = 52)	Placebo Treatment Group (n = 51)
Gastrointestinal tract
Nausea	31/50 (62.0)	16/50 (32.0)	.008
Diarrhea	10/50 (20.0)	7/50 (14.0)	.42
Constipation	18/50 (36.0)	11/50 (22.0)	.16
Vomiting	15/49 (30.6)	9/50 (18.0)	.09
Dyspepsia	17/50 (34.0)	11/50 (22.0)	.54
Abdominal pain	23/50 (46.0)	13/50 (26.0)	.06
Cardiovascular
Palpitation	1/50 (2.0)	0	.25
Orthostatic hypotension	4/49 (8.2)	0	.04
Infection
Upper respiratory tract	9/50 (18.0)	9/50 (18.0)	.82
Influenza virus	1/50 (2.0)	2/51 (3.9)	.47
Others	2/50 (4.0)	0	.21
Nervous system
Fatigue	1/50 (2.0)	1/50 (2.0)	.81
Headache	10/50 (20.0)	8/50 (16.0)	.51
Dizziness	4/50 (8.0)	3/51 (5.9)	.95
Injection site
Hematoma or pain	0	3/51 (5.9)	.13
Musculoskeletal disorder	3/49 (6.1)	2/51 (3.9)	.47
Other	2/50 (4.0)	6/51 (11.8)	.20
Hypoglycemiac	13/50 (26.0)	7/50 (14.0)	.22
Serious adverse events
Total No.	6/51 (11.8)	13/51 (25.5)	.04
Somatic disease
Tonsillitis	0	1/50 (2.0)	.39
Pneumonia	2 (3.9)	0	.40
Bacterial gastroenteritis	0	1/50 (2.0)	.40
Cholelithiasis	0	1/50 (2.0)	.40
Hashimoto disease	0	1/50 (2.0)	.40
Death	1/52 (1.9)	0	.30
Psychiatric disease
Admission to hospital for worsening of schizophrenia	3/50 (6.0)	951 (17.7)	.08

^aAll participants who received at least 1 dose of liraglutide or placebo were included in the safety analyses.

^bCalculated using exact logistic regression adjusting for antipsychotic treatment (olanzapine, clozapine, or both).

^cBased on self-reported cases of hypoglycemia or plasma glucose levels less than 54 mg/dL (to convert to mmol/L, multiply by 0.0555) measured during the trial. All cases of measured hypoglycemia happened during the final oral glucose tolerance test in participants who had received placebo.